London: AstraZeneca (LON:AZN) Stock Has Just Had Its “Accumulate” Rating Reiterated by Handelsbanken. Shares now Have a GBX 4959.33 Target


AstraZeneca (LON:AZN) Rating Reaffirmed

Recently, In an interesting research report revealed to clients and investors on Friday, 4 December, AstraZeneca (LON:AZN) shares have had their “Accumulate” Rating reconfirmed by investment advisers at Handelsbanken, who currently has a GBX 4959.33 Estimated Target Price on company. This target by Handelsbanken suggests the possibile upside of 11.26% from the last stock close price.

From a total of 29 analysts covering AstraZeneca PLC (LON:AZN) stock, 18 rate it a ”Buy”, 6 a “Sell”, and 10 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is GBX 94.17 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 70.59 with a 8.53% above today’s (GBX 4451.5) stock price. AstraZeneca PLC was the topic of 117 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Morgan Stanley upgraded shares on December 1 to “Overweight” rating. Credit Suisse maintained shares with “Underperform” rating and GBX 4000 target share price in a report from a November 24. Deutsche Bank maintained AZN stock in a recent report from November 30 with “Buy” rating. Helvea maintained the rating on November 23. Helvea has a “Hold” rating and a GBX 4400 price target on shares. Finally, Goldman Sachs maintained the stock with “Neutral” rating in a report issued on a November 24.

Approximately 482,958 shares of stock traded hands. AstraZeneca plc (LON:AZN) has risen 1.43% since May 7, 2015 and is uptrending. It has outperformed by 4.21% the S&P500.

London: AstraZeneca (LON:AZN) Stock Has Just Had Its

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 55.53 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.3 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.” Get a free copy of the Zacks research report on AstraZeneca plc (AZN).